Skip to content

Cancer Health Center

Font Size

Treatment Option Overview

    Table 6. Relationship Between Tyrosine Kinase Genotype and Response to Imatinib Therapya

    European Phase I/IIb Trial, % (n)[31]B-2222 Phase IIc Trial, % (n)[32]European/Australasian Phase IIId Trial, % (n)[18]North AmericanCLB-80004Phase IIIe Trial, % (n)[33]
    N = number in sample, number of observations; NR = not reported.
    a Annual review of pathology by ANNUAL REVIEWS, INC. Reproduced with permission of ANNUAL REVIEWS, INC., in the format Internet posting via Copyright Clearance Center.[3]
    b[Level of evidence: 1iiA, 1iiDii,1iiDiv (Phase 1) and2A; 2Div(Phase II)]
    c[Level of evidence: 1iiDiv]
    d[Level of evidence: 1iiAand1iiDiii]
    e[Level of evidence: 1iiDiv]
    f Defined as complete or partial response by Southwest Oncology Group (SWOG) criteria for B-2222 or RECIST (Response EvaluationCriteria in Solid Tumors) for all other trials; excludes nonevaluable patients.
    g Statistically significant difference compared toKIT9 and wild-type (noKITorPDGFRAmutation) groups.
    Study participants(N = 37)(N = 127)(N= 377)(N = 324)
    Objective responsef 
    KITexon 1183 (24)83g(85)70g(248)67g(211)
    KIT exon 925 (4)48 (23)35 (58)40 (25)
    Wild-type33 (6)0 (9)25 (52)39 (33)
    Progressive disease 
    KIT exon 11453NR
    KIT exon 901717NR
    Wild-type335619NR

    Kinase genotype appears to correlate with progression-free survival (PFS) and OS. The median time to tumor progression (TTP) for patients whose GIST harbors a KIT exon 11 mutation has been reported to be more than 1 year longer than the median TTP for patients whose tumors have KIT exon 9 or wild-type kinase genotypes; a similar OS benefit has been reported for patients with KIT exon 11 mutations versus the other common genotype subsets.[3] In a subset analysis of the European/Australasian phase III trial, it was found that the PFS of GIST patients with KIT exon 9 mutations was significantly better when patients were treated with 800 mg of imatinib per day as compared with 400 mg per day (P = .0013), with a reduction of relative risk of 61%.[18][Level of evidence: 1iiDiii] Accordingly, routine tumor typing and imatinib dose selection based on the presence or absence of a KIT exon 9 mutation is recommended by some but not all GIST experts.[3,4]

    1|2|3|4|5

    Today on WebMD

    Colorectal cancer cells
    A common one in both men and women.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Do you know the symptoms?
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article